Surveys,Polls & Research

Genscript Biotech Reports Full Year 2020 Financial Results

Gross profit of the Group for the year ended December 31, 2020 was approximately US$255.9 million, representing an increase of 41.9% as compared with approximately US$180.3 million recorded for the year ended December 31, 2019

  • Revenue of the Group for the year ended December 31, 2020 was approximately US$390.8 million, representing an increase of 42.9% as compared with approximately US$273.4 million for the year ended December 31, 2019 Genscript Biotech Reports Full Year 2020 Financial Results
  • The adjusted net profit* of non-cell therapy business was approximately US$44.4 million, representing an increase of 105.6% as compared with approximately US$21.6 million for the year ended December 31, 2019, and the adjusted net loss* of cell therapy business was approximately US$213.3 million, whilst the adjusted net loss* of cell therapy business was approximately US$131.9 million for the year ended December 31, 2019
  • Loss of the Group for the year ended December 31, 2020 was approximately US$281.4 million, whilst loss was approximately US$117.5 million for the year ended December 31, 2019. The adjusted net loss* of the Group was approximately US$168.9 million, whilst the adjusted net loss* of approximately US$110.3 million was recorded for the year ended December 31, 2019

NANJING, China, March 26, 2021 /PRNewswire/ — Genscript Biotech (HKEX: 1548.HK) (GenScript), a global leading biotech company, today announced its audited financial results for the year ended December 31, 2020.

“In 2020, the outbreak of COVID-19 pandemic presented both challenges and opportunities to the life science community. Thanks to concerted efforts of all GenScript people, the Group delivered historically strong results amid the outbreak,” said Patrick Liu, Rotating CEO of GenScript. “In the past year, our business segments tided over difficulties, turned challenges into opportunities and achieved many breakthroughs. In the future, we will move forward with dedication and create more value for both our investors and customers. We are committed to our mission of “making people and nature healthier through biotechnology” and strive for human wellbeing.”

Financial Results Highlits for the Year Ended December 31, 2020

Revenue                                            

In 2020, the Group recorded revenue of  approximately US$390.8 million, representing an  increase of 42.9% from approximately US$273.4 million in 2019. This was primarily attributable to (i) the strong growth in business of specially-functioned protein and antibody which meet market demands on key products related to COVID-19, (ii) the continuing increase from life-science services and products from major strategic customers and new competitive services and products, (iii) the  increase of contract revenue derived from Legend’s collaboration with Janssen with new milestone achieved, and (iv) the increase in both the number of customers and their purchase volume of industrial synthetic biology products.

Gross Profit

In 2020, the Group’s gross profit increased by 41.9% to approximately US$255.9 million from approximately US$180.3 million in 2019. The increase in gross profit was primarily attributable       to the (i) strong growth in life-science and biologics development business and high gross margin products, especially for COVID-19, and (ii) significant improvement on capacity utilization of materials and labor efficiency in industrial synthetic biology products.

Selling and distribution expenses

The selling and distribution expenses increased by 52.4% to approximately US$107.3 million in    2020 from approximately US$70.4 million in 2019. This was mainly attributable to the (i) increased investment into the commercial talent pool by recruiting more experienced personnel and improving incentive packages, and (ii) increased expenses for the global expansion of our business.

Administrative expenses

In 2020, the administrative expenses increased by 63.3% to approximately US$90.3 million from US$55.3 million in  2019. This was  mainly caused by  (i)  competitive compensation package for  our employees including shared-based payment provided to recruit experienced talents for all business segments, (ii) the reinforcement of some key administrative functions such as information technology, supply chain and finance to build up capable and professional administrative team to support the Group’s overall business expansion, and (iii) the expansion of the European and Asia- Pacific Regional centers to accelerate the Group’s global market penetration.

Research and development expenses

The  research and  development expenses increased by  41.6% to  approximately US$263.4 million  in 2020 from approximately US$186.0 million in 2019. This was mainly due to the (i)  investment    in COVID-19 related projects and other new challenging  research  and  development  projects,  which significantly strengthened our competitiveness in the market and improved our production efficiency, (ii) increase in clinical trial expenses and preclinical study costs, especially in the cell therapy segment, and (iii) increase in compensation package including shared-based payment for research and development personnel.

*Adjusted net profit/(loss)

 

Non-cell

therapy

US$’000

 

Cell therapy

US$’000

 

Total

US$’000

Net profit/(loss)

22,054

 

(303,477)

 

(281,423)

Excluding: Share-based payment expenses, net of tax

10,904

 

4,760

 

15,664

Exchange differences, net of tax

6,526

 

(66)

 

6,460

Consultation expenses for the Investigation, net of tax

1,086

 

 

1,086

Impairment loss on goodwill, other intangible assets and

long-term investments, net of tax

3,806

 

 

3,806

Fair value loss of convertible redeemable preferred shares

 

79,984

 

79,984

Service fee for the issuance of Legend Series A Preference Shares

 

4,014

 

4,014

Spin-off expenses relating to the separate listing of Legend

24

 

1,439

 

1,463

Adjusted net profit/(loss)

44,400

 

(213,346)

 

(168,946)

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

 
   

REVENUE

2020

US$’000

390,846

 

2019

US$’000

273,354

Cost of sales

(134,953)

 

(93,064)

Gross profit

255,893

 

180,290

Other income and gains

24,795

 

21,185

Selling and distribution expenses

(107,341)

 

(70,358)

Administrative expenses

(90,341)

 

(55,256)

Research and development expenses

(263,401)

 

(186,022)

Fair value loss of convertible redeemable preferred shares

(79,984)

 

Finance costs

(5,432)

 

(781)

Other expenses

(15,497)

 

(589)

Share of losses of associates

(599)

 

(308)

Reversal of/(provision for) impairment of financial assets, net

7

 

(1,851)

LOSS BEFORE TAX

(281,900)

 

(113,690)

Income tax credit/(expense)

477

 

(3,826)

LOSS FOR THE YEAR

(281,423)

 

(117,516)

       

Attributable to: Owners of the parent

(204,945)

 

(96,912)

Non-controlling interests

(76,478)

 

(20,604)

 

(281,423)

 

(117,516)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

 

NON-CURRENT ASSETS

2020

US$’000

 

2019

US$’000

Property, plant and equipment

345,215

 

235,986

Advance payments for property, plant and equipment

5,906

 

8,585

Investment properties

7,726

 

7,442

Right-of-use asset

34,017

 

29,642

Goodwill

14,116

 

15,245

Other intangible assets

26,020

 

25,482

Investment in associates

3,433

 

2,615

Financial assets at fair value through profit or loss

10,555

 

4,667

Other non-current asset

3,542

 

Deferred tax assets

3,702

 

5,701

Total non-current assets

454,232

 

335,365

CURRENT ASSETS

Inventories

31,745

 

16,486

Contract costs

5,785

 

3,369

Trade and notes receivables

141,748

 

73,067

Prepayments, other receivables and other assets

32,834

 

31,621

Financial assets at fair value through profit or loss

5,866

 

25,434

Loans to an associate

2,422

 

2,007

Restricted cash

7,471

 

972

Time deposits

136,245

 

148,693

Cash and cash equivalents

629,058

 

252,397

Total current assets

993,174

 

554,046

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

 
   

CURRENT LIABILITIES

2020

US$’000

 

2019

US$’000

Trade and bills payables

23,376

 

17,627

Other payables and accruals

168,980

 

125,035

Interest-bearing bank borrowings

44,642

 

17,008

Lease liabilities

2,588

 

1,769

Tax payable

3,532

 

2,846

Contract liabilities

84,414

 

60,130

Government grants

379

 

90

Total current liabilities

327,911

 

224,505

NET CURRENT ASSETS

665,263

 

329,541

TOTAL ASSETS LESS CURRENT LIABILITIES

1,119,495

 

664,906

NON-CURRENT LIABILITIES

Interest-bearing bank loans

1,260

 

1,748

Lease liabilities

6,513

 

3,608

Contract liabilities

277,052

 

277,827

Deferred tax liabilities

7,030

 

5,582

Government grants

11,495

 

3,843

Other non-current liability

554

 

Total non-current liabilities

303,904

 

292,608

NET ASSETS

815,591

 

372,298

       

EQUITY

     

Equity attributable to owners of the parent

Share capital

1,954

 

1,879

Treasury shares

(16,712)

 

(7,774)

Reserves

916,463

 

388,699

 

901,705

 

382,804

Non-controlling interests

(86,114)

 

(10,506)

TOTAL EQUITY

815,591

 

372,298

About GenScript Biotech Corporation

GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. Based on its leading gene synthesis technology, GenScript has developed four major platforms including the global cell therapy platform, the biologics contract development and manufacturing organization (CDMO) platform, the contract research organization (CRO) platform and the industrial synthesis product platform. GenScript’s business operation spans over 100 countries and regions worldwide with legal entities located in the US, the Chinese mainland, Hong Kong of China, Japan, Singapore, Netherlands and Ireland.

This news was shared to Prittle Prattle News via press release.

By PR Newswire

Also read BRF

Related Posts

1 of 39